Literature DB >> 11677996

Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis.

S Tsujitani1, S Oka, K Suzuki, H Saito, A Kondo, M Ikeguchi, M Maeta, N Kaibara.   

Abstract

BACKGROUND/AIMS: The relationship between prognostic factors and survival time after noncurative gastric resection in patients with advanced gastric cancer was examined by a retrospective review of data on 364 patients.
METHODOLOGY: There were 168 patients without metastasis to the liver or peritoneum (group A), 127 with peritoneal metastasis and no liver metastasis (group B), 50 with liver metastasis and no peritoneal metastasis (group C) and 19 with synchronous liver and peritoneal metastases (group D). Patients were primarily treated with the following 3 drugs: the fluorinated pyrimidines, cisplatin, and mitomycin C.
RESULTS: Patients in group D had a very poor prognosis as compared with the other groups. Multivariate analysis using the Cox's proportional hazard model adjusted for sex, age, and other covariants indicated that lymph node metastasis, lymph node dissection, and fluorinated pyrimidines for group A, cisplatin for group B, and lymph node dissection for group C were independent prognostic factors. An analysis of patients excluding cases who died within 30 days after surgery revealed that lymph node dissection for group A, lymph node dissection and cisplatin for group B, and lymph node dissection for group C were independent prognostic factors.
CONCLUSIONS: Treatment protocol specific for the residual disease may improve the survival of patients with advanced gastric cancer treated by noncurative resection.

Entities:  

Mesh:

Year:  2001        PMID: 11677996

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?

Authors:  Reza F Saidi; Stephen G ReMine; Paul S Dudrick; Nader N Hanna
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

2.  Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.

Authors:  Feihu Bai; Jie Liang; Jun Wang; Yongquan Shi; Kedong Zhang; Shuhui Liang; Liu Hong; Huihong Zhai; Yuanyuan Lu; Yu Han; Fang Yin; Kaichun Wu; Daiming Fan
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

3.  Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Authors:  Seung Tae Kim; In Kyoung Lee; Eran Rom; Roy Sirkis; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Kyoung-Mee Kim; Avner Yayon; Jeeyun Lee
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model.

Authors:  Jiryeon Jang; Hee Kyung Kim; Heejin Bang; Seung Tae Kim; Sun Young Kim; Se Hoon Park; Ho Yeong Lim; Won Ki Kang; Jeeyun Lee; Kyoung-Mee Kim
Journal:  Transl Oncol       Date:  2017-05-11       Impact factor: 4.243

5.  MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.

Authors:  Ji Yun Lee; InKyoung Lee; Won Jin Chang; Su Min Ahn; Sung Hee Lim; Hae Su Kim; Kwai Han Yoo; Ki Sun Jung; Haa-Na Song; Jin Hyun Cho; Sun Young Kim; Kyoung-Mee Kim; Soojin Lee; Seung Tae Kim; Se Hoon Park; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  Oncotarget       Date:  2016-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.